CULVER CITY, Calif.--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, announced today the appointment of Sandeep (Bobby) Reddy, MD, as Chief Medical Officer. In his new position, Dr. Reddy will be responsible for overseeing education, outreach, clinical development programs, and clinical trials for GPS Cancer™, a comprehensive, molecular profile and NantHealth's proprietary revolutionary pan-omic cancer analytic platform.
“Appointing Dr. Reddy and his experience to our leadership team will be highly valuable to the evolution of the GPS Cancer initiative,” said Dr. Patrick Soon-Shiong, founder and CEO of NantHealth. “With extensive background in hematology, medical oncology and therapeutics research, Dr. Reddy will play a key role in helping NantHealth achieve victory in the war against cancer.”
Dr. Reddy joined NantHealth in December of 2016 as Senior Executive Director of Medical Affairs and prior to that position, he served as Chief Medical Officer at Caris Life Sciences. Over the course of his career, Dr. Reddy has produced over 100 abstracts at major medical conferences and over 30 peer-reviewed publications since 2014.
“The milestones that NantHealth has achieved in just over a year have established the company as a proven disrupter – national and international insurance coverage of the GPS Cancer profile, multiple partnerships with leading medical institutions and joining experts in the cancer community are immense efforts to take on and in such a condensed timeframe,” said Dr. Reddy. “I’m thrilled to be a part of an initiative that has potential to change the way we approach and treat cancer. Dr. Soon-Shiong is a true visionary and I’m looking forward to working with such an inspirational group of leaders to build further awareness of the benefits that GPS Cancer has to offer the oncology market.”
Dr. Reddy’s additional experience includes servicing as Chief of Staff at Los Alamitos Medical Center and actively practicing clinical hematology and oncology. Simultaneously, he held an adjunct faculty position at the Geffen/UCLA School of Medicine as a clinical instructor at Harbor-UCLA Medical Center, where he was awarded the distinguished teaching award for clinical faculty in 2006. He is a member of the Los Angeles Biomedical Institute, American Society of Clinical Oncology (ASCO), International Association for the Study of Lung Cancer (IASLC) and current SWOG investigator. His medical training includes fellowship training in hematology and medical oncology and therapeutics research at the City of Hope in Duarte, CA and Internal Medicine residency at Harbor-UCLA Medical Center. Dr. Reddy received his MD from the Geffen/UCLA School of Medicine after receiving his BS in biomedical sciences at the University of California, Riverside.
Cautionary Note Concerning Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the capabilities and anticipated utility of our GPS Cancer, including predicting patient response and resistance to therapeutics, enabling diagnoses by physicians and accelerating efforts to bring novel combinations of therapeutic agents to cancer patients. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results. Factors that may cause future results to differ materially from management’s current expectations include, among other things, that GPS Cancer may not perform as anticipated, that sufficient physicians may not adopt GPS Cancer to assist their diagnoses or that healthcare payers may not provide reimbursement for GPS Cancer as expected. Our business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of our products; our ability to successfully launch new products and applications; competition; our sales, marketing and distribution capabilities; our planned sales, marketing, and research and development activities; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting our business and operating results can be found in our existing and future filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements except as may be required by law.
About NantHealth, Inc.
NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth's unique systems-based approach to personalized healthcare applies novel diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with large-scale, real-time biometric signal and phenotypic data to track patient outcomes and deliver precision medicine. For nearly a decade, NantHealth has developed an adaptive learning system, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets billions of molecular, clinical, operational and financial data points derived from novel and traditional sources, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time. For more information please visit www.nanthealth.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
About GPS Cancer™
GPS Cancer™ is a unique, molecular scan available through NantHealth. GPS Cancer integrates whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics through mass spectrometry, providing oncologists with a comprehensive molecular profile of a patient's cancer and an assessment of protein pathway function to inform personalized treatment strategies. GPS Cancer scanning is conducted in CLIA-certified and CAP-accredited laboratories, and is a key enabler for Cancer Breakthroughs 2020, the world's most comprehensive cancer collaborative initiative seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients. For more information, visit www.gpscancer.com.
